Nautilus Biotechnology, Inc. (NAUT)

NCM – Real Time Price. Currency in USD

0.88

-0.01 (-0.76%)

Market open: Aug 12, 2026, 1:51 PM EDT

0.89

+0.00 (0.46%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

03.08.2026

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027.

Videos

No Data

There is no data to display

Nautilus Biotechnology, Inc. (NAUT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Videos

No Data

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Videos

No Data

Search stocks

Nautilus Biotechnology, Inc. (NAUT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Videos

No Data

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Videos

No Data